Valuation
26% of the score, 30% here after data gaps
91median 53
ADMA Biologics, Inc. is valued at 10.9x its operating profit, including debt: a low multiple.
60x
50x
35x
25x
18x
12x
8x
10.9x
Full points at 8x or less, none from 60xfull points
ADMAADMA Biologics, Inc.
$10.68-27% 1Y
$10.68
$7.6052 weeks$20.38
RyuScore
Seven criteria, each scored 0 to 100 on a published scale, weighted into one number.
RyuScore 69 out of 100, Above average
Today's price. Only valuation depends on it.
Above average. ADMA Biologics, Inc. scores higher than 74% of the 2,231 companies Ryufin scores.
Carried by valuation and return on new capital, held back by return on capital and capital allocation.
Healthcare median 19 · all companies 55
How the score has moved
At each fiscal year end, from the reports and price of the time0
0
11
17
26
58
69
202020212022202320242025today
The biggest move was up 32 points from 2024 to 2025, mostly return on new capital.
Return on capital
18% of the score, 20% here after data gaps
40median 24
Over 7 years the business earned 7.3% a year after tax on the capital it uses.
2%
8%
15%
25%
7.3%
None at 2% or less, full points from 25%full points
7 years agolatest 39%
Return on new capital
16% of the score, 18% here after data gaps
100median 33
For every dollar of operating profit earned over 6 years, yearly profit grew by 98 cents. New capital earned 88%, and 111% of profit went back into the business.
-5%
12%
98%
None at minus 5 cents, full points from 12 centsfull points
Capital allocation
14% of the score, 16% here after data gaps
40median 63
How management spends the money: shares bought back or issued, and whether assets grow faster than the business they serve.
Share countUp 23.2% a year over 5 years: new shares
05%
-3%
23%
0 pointsfull points
Assets against salesAssets grew 25% a year, sales 65%
10012%
-2%
-40%
0 pointsfull points
Cycle position
Taken out: its 12% is shared by the others
n/ano data
Margins have been too thin to measure a cycle against.
Balance sheet
8% of the score, 9% here after data gaps
100median 50
What the debt weighs against the profit that has to carry it.
Net debt to EBITDA0.3x a year of EBITDA
1004.5x
0.5x
0.3x
0 pointsfull points
Interest coverOperating profit covers interest 25x
1001.5x
12x
25.4x
0 pointsfull points
Earnings quality
6% of the score, 7% here after data gaps
0median 90
Whether the reported profit arrives as cash, and whether the accounts show the usual signs of stretching.
Cash against profitOperating cash flow was 0.56x profit over 3 years
00.7x
1x
1.3x
0.6x
0 pointsfull points
AccrualsProfit ran ahead of cash by 17.3% of assets
08%
0%
-8%
17%
0 pointsfull points
Beneish M-score-0.18, above the usual warning line
0-1.50
-1.78
-2.22
-3.00
-0.18
0 pointsfull points
How the RyuScore works
Each criterion earns 0 to 100 points on the scale drawn under it, and the RyuScore is their average weighted 26, 18, 16, 14, 12, 8 and 6. Scales bend in the company's favour between their ends, so an ordinary figure is never already near zero. For ADMA, cycle position could not be measured from the filings, so it is taken out and the remaining weights scale up.
Built from the company's annual and quarterly filings with the SEC and today's share price. Banks, insurers and property trusts are not scored: their debt is their raw material, so these yardsticks mean something else there. Figures as of 2026-06-30, latest annual report FY2025.
On our screens:Quality at a reasonable price